General Information

Stock Quote

ABMD (Common Stock)
Exchange NASDAQ (US Dollar)
Price   $61.24
Change (%)   Stock is Up  1.09  (1.81%)
Volume   305,000
Data as of 03/04/15 4:00 PM ET
Minimum 20 minute delay
Refresh quote

Corporate Profile

Abiomed (NASDAQ: ABMD) is a global technology leader focused on RECOVERING HEARTS AND SAVING LIVES.

Abiomed CEO, Chairman, and President, Michael R. Minogue, has focused the company’s efforts on developing ground-breaking technologies designed to assist or replace the life-sustaining pumping function of the failing heart. The Company’s portfolio of products and services offer healthcare professionals an array of choices across a broad clinical spectrum. From the world’s first total replacement heart to the World’s Smallest Heart Pump, 1/100th the size of the heart with rapid and simple insertion, Abiomed is dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.

More>>

More »   Recent News

Date Title  
02/25/15

DANVERS, Mass., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Robert L. Bowen, Vice President & Chief Financial Officer, will present at the Cowen and Company 35th Annual Health Care Conference on Wednesday, March 4, 2015 at 11:20 a.m. EST. The conf...

02/04/15

DANVERS, Mass., Feb. 4, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and CEO, will present at the 2015 Leerink Global Healthcare Conference on February 11, 2015 at 1:00 p.m. EST. The conference will be held at The Wal...

01/27/15

DANVERS, Mass., Jan. 27, 2015 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that the Impella RP® (Right Percutaneous) System has received U.S. Food and Drug Administration (FDA) approval under a Humanitarian Device Exemption (HDE). This innovative medical device i...

01/27/15

DANVERS, Mass., Jan. 27, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported third quarter fiscal 2015 revenue of $62.0 million, up 34% compared to revenue of $46.2 million in the same period of fiscal 2014, and a third quarter fiscal 2015 GAAP net income of $12.7 milli...

01/26/15

DANVERS, Mass., Jan. 26, 2015 (GLOBE NEWSWIRE) -- In response to the state of emergency declared in Massachusetts due to the impending winter storm tomorrow, Abiomed, Inc. (Nasdaq:ABMD) is announcing that it will reschedule its third quarter fiscal 2015 earnings release and conference call. The call, originally scheduled for Tuesday, January 27...